Presentation today, page-2

Most of the presentation was, as usual, repeating what has happened. Looks to me that ATH owns more of PBT2, than I thought, they do not talk about charging the royalties at some clear % level, but they will pay to Queensland when ATH gets some money from the patent. I hope I understood this correctly. Nothing about this was told directly. They do not know exactly how to go forward with PBT2, no estimate of the market value of it was told. A deal with a big pharma seems not to be in immediate plans, something needs to be done first with it and they feel that that is not going to cost anything to ATH. Just as was told earlier in December.
There will be several presentations in congresses, now the MSA conference, AAN conference, and also a conference in the autumn. Mitochondrion studies will be done explaining how ATH434 works (external consultants?) Nothing new from the ape study.
I would hope there would be some written form about this to check the facts to avoid misunderstandings. Please, correct me if you understood something differently.